First-in-human listings bring a bispecific and yet another in vivo Car-T.
ApexOnco Front Page
Recent articles
But the Astra/Daiichi ADC stumbles in lung cancer.
The company is starting four new pivotal trials this year.
Cafelkibart’s entry into phase 3 is of note to Coherus.
The company quietly discontinues AlphaMedix.
Tecvayli and Hernexeos might get speedy approval decisions.
The group’s CD47 x CD20 fusion protein will soon go into a Chinese phase 3.
RMC-5127 becomes the company’s fourth clinical project.
